OncoMatch/Clinical Trials/NCT06424067
Phase 2 Study of Fingolimod in Lung Cancers
Is NCT06424067 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fingolimod 0.5 milligram (mg) [Gilenya] for non small cell lung cancer.
Treatment: Fingolimod 0.5 milligram (mg) [Gilenya] — This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Baseline lymphocyte count >1000 cells/mL
Baseline lymphocyte count >1000 cells/mL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hollings Cancer Center at Medical University of South Carolina · Charleston, South Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify